MA27664A1 - Acides gras a chaine moyenne, glycerides et analogues utilises en tant que stimulateurs de l'erythropoiese - Google Patents

Acides gras a chaine moyenne, glycerides et analogues utilises en tant que stimulateurs de l'erythropoiese

Info

Publication number
MA27664A1
MA27664A1 MA28479A MA28479A MA27664A1 MA 27664 A1 MA27664 A1 MA 27664A1 MA 28479 A MA28479 A MA 28479A MA 28479 A MA28479 A MA 28479A MA 27664 A1 MA27664 A1 MA 27664A1
Authority
MA
Morocco
Prior art keywords
erythroposis
stimulators
glycerides
fatty acids
chain fatty
Prior art date
Application number
MA28479A
Other languages
English (en)
Inventor
Christopher Penney
Lyne Gagnon
Pierre Laurin
Boulos Zacharie
Original Assignee
Prometic Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biosciences Inc filed Critical Prometic Biosciences Inc
Publication of MA27664A1 publication Critical patent/MA27664A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation d'une composition comprenant un composé représenté par la formule I, II, IIa, III ou IIIa; ou une combinaison de celles-ci, dans lesquelles chaque R1 représente indépendamment alkyle C7-11; A et B représentent indépendamment H ou CO-R1; R2 représente H ou alkyle C1-4; M représente un monocation (k=1) ou un dication (k=2) métallique ; Y vaut 0 ou NH; et Z vaut 0, NH, CH2O ou une liaison; pour la fabrication d'un médicament pour la stimulation de l'érythropoïèse. La composition comprend de préférence de l'érythropoïétine humaine.
MA28479A 2003-02-07 2005-09-05 Acides gras a chaine moyenne, glycerides et analogues utilises en tant que stimulateurs de l'erythropoiese MA27664A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44545403P 2003-02-07 2003-02-07

Publications (1)

Publication Number Publication Date
MA27664A1 true MA27664A1 (fr) 2005-12-01

Family

ID=32850990

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28479A MA27664A1 (fr) 2003-02-07 2005-09-05 Acides gras a chaine moyenne, glycerides et analogues utilises en tant que stimulateurs de l'erythropoiese

Country Status (28)

Country Link
US (1) US9682054B2 (fr)
EP (1) EP1592416B1 (fr)
JP (1) JP5390070B2 (fr)
KR (1) KR101120775B1 (fr)
CN (1) CN100427081C (fr)
AP (1) AP2005003367A0 (fr)
AR (1) AR043120A1 (fr)
AT (1) ATE419846T1 (fr)
AU (1) AU2004210193B2 (fr)
BR (1) BRPI0407276A (fr)
CA (1) CA2515160C (fr)
CY (1) CY1108963T1 (fr)
DE (2) DE602004018902D1 (fr)
DK (1) DK1592416T3 (fr)
EA (1) EA009939B1 (fr)
ES (1) ES2255467T3 (fr)
IL (1) IL170057A (fr)
JO (1) JO2705B1 (fr)
MA (1) MA27664A1 (fr)
MX (1) MXPA05008382A (fr)
MY (1) MY140913A (fr)
NO (1) NO334085B1 (fr)
NZ (1) NZ541593A (fr)
PT (1) PT1592416E (fr)
SI (1) SI1592416T1 (fr)
TN (1) TNSN05189A1 (fr)
WO (1) WO2004069237A1 (fr)
ZA (1) ZA200506246B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL158322A0 (en) * 2001-04-18 2004-05-12 Prometic Biosciences Inc Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
US20050232981A1 (en) * 2004-04-15 2005-10-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
JP2008507288A (ja) 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
WO2006024174A1 (fr) * 2004-09-03 2006-03-09 Prometic Biosciences Inc. Derives de purinyle substitues a activite immunomodulatrice et chimioprotectrice et utilisation de ces derniers seuls ou avec des acides gras a longueur de chaine moyenne ou avec des glycerides
US8071580B2 (en) 2004-10-01 2011-12-06 Prometic Biosciences Inc. Medium-chain length fatty alcohols as stimulators of hematopoiesis
AP2007003968A0 (en) 2004-10-01 2007-04-30 Prometic Biosciences Inc Medium-chain length fatty alcohols as stimulators of hematopoiesis
KR20150115961A (ko) 2005-11-23 2015-10-14 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US9526759B2 (en) 2007-02-01 2016-12-27 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TW201940502A (zh) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
PT2120999E (pt) 2007-02-09 2012-12-10 Acceleron Pharma Inc Antagonista de activina-actriia e usos para promover o crescimento ósseo em doentes de cancro
WO2009038745A1 (fr) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Antagonistes de l'activine-actriia et utilisations pour réduire ou empêcher la sécrétion de fsh
MY151439A (en) * 2007-11-02 2014-05-30 Prometic Biosciences Inc Medium-chain length fatty acids and glycerides as nephroprotection agents
BRPI0821395A2 (pt) * 2007-12-19 2015-06-16 Prometic Biosciences Inc Triglicerídeos, sais e ácidos graxos de cadeia média em combinação com gemcitabina para tratamento de câncer pancreático
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
DK2340031T3 (da) 2008-08-14 2019-07-15 Acceleron Pharma Inc Gdf-fanger til anvendelse ved behandling af anæmi
HUE033611T2 (en) 2008-09-17 2017-12-28 Chiasma Inc Pharmaceutical preparations and associated dosing procedures
MX355042B (es) 2009-06-08 2018-04-02 Acceleon Pharma Inc Metodos para aumentar adipositos termogenicos.
EP3805259A1 (fr) 2009-06-12 2021-04-14 Acceleron Pharma Inc. Protéines de fusion actriib-fc tronquées
CN105561295B (zh) * 2009-08-13 2020-03-20 阿塞勒隆制药公司 Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平
ES2658292T3 (es) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
WO2012064771A1 (fr) 2010-11-08 2012-05-18 Acceleron Pharma, Inc. Agents de liaison à actriia et leurs utilisations
TWI572352B (zh) * 2012-03-01 2017-03-01 波麥堤克藥學Ｓｍｔ有限公司 用於製備具中鏈長度之脂肪酸的三酸甘油酯之方法
ES2884095T3 (es) 2012-11-02 2021-12-10 Celgene Corp Antagonistas de activina-actrii y usos para el tratamiento de trastornos óseos y otros trastornos
CN102973922B (zh) * 2012-12-18 2016-02-03 华东理工大学 一种融合蛋白的应用
TN2016000553A1 (en) 2014-06-13 2018-04-04 Acceleron Pharma Inc Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
EP4233889A3 (fr) 2014-12-03 2023-10-11 Celgene Corporation Antagonistes de l'activine-actrii et leurs utilisations pour le traitement du syndrome myelodysplasique
CA2975599A1 (fr) 2015-02-03 2016-08-11 Chiasma Inc. Methode de traitement de maladies
US20170021029A1 (en) * 2015-04-15 2017-01-26 Jeffrey Charles Raber Topical formulations and uses
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871768A (en) 1984-07-12 1989-10-03 New England Deaconess Hospital Corporation Dietary supplement utilizing ω-3/medium chain trigylceride mixtures
US6054441A (en) 1987-10-28 2000-04-25 Pro-Neuron, Inc. Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis
US5011852A (en) 1988-07-25 1991-04-30 Applied Analytical Industries, Inc. Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
JP3014119B2 (ja) * 1990-05-28 2000-02-28 雪印乳業株式会社 直腸投与用赤血球造血剤
JP3249147B2 (ja) 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
DE69124357T2 (de) * 1991-01-15 1997-07-10 Hemosphere Inc Protein Nanomatrizen und Verfahren zur Herstellung
JPH05163160A (ja) 1991-12-13 1993-06-29 Snow Brand Milk Prod Co Ltd 免疫低下に伴う感染症の予防及び治療用栄養剤
US5214035A (en) 1992-04-16 1993-05-25 Hoechst-Roussel Agri-Vet Company Thixotropic formulations
US5318781A (en) * 1993-04-06 1994-06-07 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
US20010003739A1 (en) * 1993-06-24 2001-06-14 Astrazeneca Ab Systemic administration of a therapeutic preparation
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
WO1995030413A1 (fr) 1994-05-10 1995-11-16 The Kitasato Institute Accelerateur de proliferation de cellules souches hematopoietiques
US5470861A (en) 1994-08-04 1995-11-28 Hoffmann-La Roche Inc. Method of promoting hair growth
US5549905A (en) 1994-10-18 1996-08-27 Clintec Nutrition Co. Enternal composition for pediatric patients
IT1275802B1 (it) 1994-11-03 1997-10-17 Hoffmann La Roche Composizione di interferone
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
AUPN933396A0 (en) 1996-04-17 1996-05-09 Pfizer Pty Limited Non-aqueuos oral-drench compositions containing avermectin compounds
US5851534A (en) 1996-05-03 1998-12-22 Dynagen, Inc. Methods for prevention and/or treatment of neutropenia
JPH10265380A (ja) 1997-03-17 1998-10-06 Bristol Myers Squibb Co 抗ガン剤
CA2303200A1 (fr) * 1997-09-04 1999-03-11 Brian C. Keller Systeme d'administration par voie orale au moyen de liposomes
WO1999025319A1 (fr) * 1997-11-14 1999-05-27 Depotech Corporation Production de liposomes multivesiculaires
ES2238775T3 (es) 1997-11-19 2005-09-01 Hercules Incorporated Suspensiones polimericas fluidificadas de polisacaridos cationicos en emolientes y su uso en la preparacion de composiciones para el cuidado personal.
DE69833333T2 (de) 1997-11-20 2006-10-19 Jhon, Gil Ja Pharmazeutische zusammensetzung enthaltend geweihextrakte von cervus nippon mit wachstumsstimulierender aktivität auf hematopoietische stammzellen und megakaryozyten
ES2224299T3 (es) * 1998-02-23 2005-03-01 Cilag Ag International Dispersion liposomal de eritroyetina.
JP4372347B2 (ja) 1998-03-11 2009-11-25 あすか製薬株式会社 発泡性腸溶製剤
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
CA2385989A1 (fr) 1999-09-27 2001-04-05 Andrew Nienstedt Compositions de composes therapeutiques solubles dans le tocol
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
DE60123603T2 (de) 2000-06-14 2007-08-16 William Leslie Diss Porter Lipide zur änderung des abwehrsystems
US6967028B2 (en) 2000-07-31 2005-11-22 Mainelab Prolonged release microspheres for injectable administration
IL142535A0 (en) 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
IL158322A0 (en) 2001-04-18 2004-05-12 Prometic Biosciences Inc Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
US20040052836A1 (en) 2002-09-13 2004-03-18 Li Luk Chiu Pharmaceutical compositions containing at least one stable liposphere having an improved shelf life
US6725510B1 (en) 2003-04-25 2004-04-27 Almetta Clyburn Inclining coffin
MXPA06000945A (es) 2003-07-25 2006-03-30 Prometic Biosciences Inc Preparacion de sales metalicas de acidos grasos de cadena mediana.
WO2006024174A1 (fr) 2004-09-03 2006-03-09 Prometic Biosciences Inc. Derives de purinyle substitues a activite immunomodulatrice et chimioprotectrice et utilisation de ces derniers seuls ou avec des acides gras a longueur de chaine moyenne ou avec des glycerides
US8071580B2 (en) 2004-10-01 2011-12-06 Prometic Biosciences Inc. Medium-chain length fatty alcohols as stimulators of hematopoiesis

Also Published As

Publication number Publication date
DK1592416T3 (da) 2009-04-20
CA2515160A1 (fr) 2004-08-19
ES2255467T3 (es) 2009-05-01
CA2515160C (fr) 2013-01-08
TNSN05189A1 (en) 2007-06-11
EA009939B1 (ru) 2008-04-28
AP2005003367A0 (en) 2005-09-30
JP2006516987A (ja) 2006-07-13
NO334085B1 (no) 2013-12-09
SI1592416T1 (sl) 2009-06-30
KR20050118671A (ko) 2005-12-19
EA200501267A1 (ru) 2006-02-24
NO20053994D0 (no) 2005-08-26
AR043120A1 (es) 2005-07-20
PT1592416E (pt) 2009-04-03
US20060128800A1 (en) 2006-06-15
NO20053994L (no) 2005-10-06
AU2004210193A1 (en) 2004-08-19
KR101120775B1 (ko) 2012-04-18
ZA200506246B (en) 2006-12-27
ATE419846T1 (de) 2009-01-15
JO2705B1 (ar) 2014-03-15
WO2004069237A1 (fr) 2004-08-19
JP5390070B2 (ja) 2014-01-15
DE602004018902D1 (de) 2009-02-26
CY1108963T1 (el) 2014-07-02
BRPI0407276A (pt) 2006-01-31
EP1592416A1 (fr) 2005-11-09
CN1753665A (zh) 2006-03-29
IL170057A (en) 2011-09-27
MY140913A (en) 2010-01-29
AU2004210193B2 (en) 2007-07-12
ES2255467T1 (es) 2006-07-01
EP1592416B1 (fr) 2009-01-07
CN100427081C (zh) 2008-10-22
US9682054B2 (en) 2017-06-20
NZ541593A (en) 2009-05-31
MXPA05008382A (es) 2005-11-04
DE04708802T1 (de) 2006-06-22

Similar Documents

Publication Publication Date Title
MA27664A1 (fr) Acides gras a chaine moyenne, glycerides et analogues utilises en tant que stimulateurs de l'erythropoiese
ATE311188T1 (de) Kombination eines angiotensin-ii antagonistisch wirkenden benzimidazols mit manidipin zur behandlung von bluthochdruck
EA200401540A1 (ru) Спироиндолинпиперидиновые производные
ATE216384T1 (de) Thiazolylbenzofuranderivate und pharmazeutische zusammensetzungen die sie enthalten
DE69008791T2 (de) Benzopyranverbindungen, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen.
ES2038172T3 (es) Procedimiento para preparar carboxamidas heterociclicas.
ATE89547T1 (de) Dopamin-vorlaeufer.
MA28286A1 (fr) Dérivés de 1-N-phenyl-amino-1H-imidazole et compositions pharmaceutiques les contenant
EA200000431A2 (ru) Новые замещенные димерные соединения, способ их получения и фармацевтические композиции, содержащие их
ES2046193T3 (es) Un procedimiento para la preparacion de un compuesto de imidazolidinona.
MX9206093A (es) Derivado de oxazolidona
BRPI0413791A (pt) composto, método para o tratamento de um indivìduo humano ou animal que sofre de, ou que é suscetìvel a um distúrbio auto-imune ou uma condição inflamatória, uso de um composto, composição farmacêutica, e, processo para a prearação de compostos
KR950701329A (ko) 벤조티아졸술폰아미드 유도체, 그의 제조법 및 그 용도(Benzothiazolesulfornamide derivative, method for preparing the same, and use thereof)
AR029468A1 (es) Derivados de aminoacidos n-mercaptoacilados, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
KR950702544A (ko) 비페닐메탄 유도체 및 이를 함유하는 약제
PL211567A1 (pl) Sposob wytwarzania zwiazku optycznie czynnego
ES2143159T3 (es) Nuevos derivados de 2-ciano-3-hidroxi-propenamidas que comprenden un radical trifluorometilsulfonilfenilo/trifluorometilsulfinilfenilo, procedimiento de preparacion, aplicacion como medicamentos y composiciones farmaceuticas que los contienen.
EP0385405A3 (fr) Dérivés d'acyle
DE69914563D1 (de) Azaindol derivate und ihre Verwendung als antithrombotische Wirkstoffe
ES528457A0 (es) Procedimiento de preparacion de nuevos derivados benzohidrilpiperacinos y sus sales de adicion acidas
DE3871160D1 (de) Prostaglandinderivate, verfahren zu ihrer herstellung und ihre pharmazeutische anwendung.
DE68909961D1 (de) 2-Aminoacetamid Derivate.
WO2000050017A3 (fr) Utilisation de derives substitues d'acides 4-biarylbutyrique et 5-biarylpentanoique pour le traitement des maladies cerebrales
DE69407227D1 (de) Die Verwendung von 2-Phenylmethylene-1-3'-(amino)-2-(hydroxy)-propoxy-imino-cyclohexane-Derivaten
ATE87004T1 (de) Fluor enthaltende makrolid-verbindungen, pharmazeutische zusammensetzungen, welche diese enthalten und ihre verwendung fuer die herstellung von arzneimitteln.